An analysis of tissue samples from Department of Oncology, Hospital Clinico de Valencia and the TCGA database for a HER2+ BC retrospective cohort confirmed a significantly lower miR-33b expression level than the breast control samples (Figure 1B and Supplementary Figure 1E). The gene discussed is ERBB2; the disease is breast cancer.